2026 Q1 -tulosraportti
38 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,14%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 28 | - | - | ||
| 12 | - | - | ||
| 1 500 | - | - | ||
| 1 710 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·53 min sittenGemini with a technical analysis of the Novo stock Here is a short and precise technical analysis of Novo Nordisk B (NOVO-B): Trend and Key Figures The stock is currently trading at 287 kr. Short and medium term: The trend is positive. The price has recently broken through resistance at 280 kr. and is above both its 20-day (286 kr.) and 50-day (267 kr.) moving averages. Long term: The trend is negative. The stock is below its 200-day moving average (304 kr.). A Death Cross has also formed (the 50-day average has crossed below the 200-day average), which is a classic sign of weakness for long-term development. Momentum: RSI (Relative Strength Index) is neutral around 52. In the short term, MACD is pointing upwards, while it continues to point downwards in the long run. Support and Resistance Resistance: The first major test is at 304 kr. (the 200-day average) and then around analysts' price target of approx. 311 kr. Support: Downwards, there is strong technical support around 246 kr., and a newer short-term support at the previous resistance level of 280 kr. Dividend and Risk The stock offers a dividend yield of 4.3 % with a healthy payout ratio of approx. 43 %. The stock's technical risk profile is currently classified as high due to an annual standard deviation of over 54 %. Without liability.
·10 t sittenUSA closing price 283kr ⬇️⬇️⬇️
11 t sitten11 t sittenUPDATE: June 12, 2026 from Jefferies The share of Novo Nordisk's Wegovy pill among total Wegovy scripts appears to have reached a plateau, hovering around one-third over the past few weeks. The latest number for the week ended on June 5 was 33%, compared with 30%, 32% and 31% in the prior weeks, according to Citi. Meanwhile, the obesity market share split between Wegovy and Eli Lilly's Zepbound has been relatively stable at around 40% to 42%, as the Indianapolis pharma's oral Foundayo makes up only a small portion of the market even though its own scripts continue to build. Wegovy's total scripts were up 9.8% on a weekly basis, reaching nearly 484,500. Within this haul, Wegovy pill contributed roughly 159,000, the oral version's highest since its launch. The drug's previous highest was 146,000 before dipping to 134,000 in our last update. Zepbound's scripts also grew week over week by 9.3%, nearing 667,400 for the week. During the same period, IQVIA tracked slightly shy of 20,000 scripts from Foundayo in its ninth week on the market, compared with nearly 17,000 the prior week. Thanks to the expansion of the oral version, Wegovy overall now commands 42.1% of the obesity market. Tracing backwards, its share has been climbing steadily, clocking in at 41.9%, 41.2%, 41.4%, 40.5%, 40.4%, 42.6% and 40.4% in the past few weeks. Source: IQVIA data cited by Jefferies
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
38 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,14%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·53 min sittenGemini with a technical analysis of the Novo stock Here is a short and precise technical analysis of Novo Nordisk B (NOVO-B): Trend and Key Figures The stock is currently trading at 287 kr. Short and medium term: The trend is positive. The price has recently broken through resistance at 280 kr. and is above both its 20-day (286 kr.) and 50-day (267 kr.) moving averages. Long term: The trend is negative. The stock is below its 200-day moving average (304 kr.). A Death Cross has also formed (the 50-day average has crossed below the 200-day average), which is a classic sign of weakness for long-term development. Momentum: RSI (Relative Strength Index) is neutral around 52. In the short term, MACD is pointing upwards, while it continues to point downwards in the long run. Support and Resistance Resistance: The first major test is at 304 kr. (the 200-day average) and then around analysts' price target of approx. 311 kr. Support: Downwards, there is strong technical support around 246 kr., and a newer short-term support at the previous resistance level of 280 kr. Dividend and Risk The stock offers a dividend yield of 4.3 % with a healthy payout ratio of approx. 43 %. The stock's technical risk profile is currently classified as high due to an annual standard deviation of over 54 %. Without liability.
- ·10 t sittenUSA closing price 283kr ⬇️⬇️⬇️
- 11 t sitten11 t sittenUPDATE: June 12, 2026 from Jefferies The share of Novo Nordisk's Wegovy pill among total Wegovy scripts appears to have reached a plateau, hovering around one-third over the past few weeks. The latest number for the week ended on June 5 was 33%, compared with 30%, 32% and 31% in the prior weeks, according to Citi. Meanwhile, the obesity market share split between Wegovy and Eli Lilly's Zepbound has been relatively stable at around 40% to 42%, as the Indianapolis pharma's oral Foundayo makes up only a small portion of the market even though its own scripts continue to build. Wegovy's total scripts were up 9.8% on a weekly basis, reaching nearly 484,500. Within this haul, Wegovy pill contributed roughly 159,000, the oral version's highest since its launch. The drug's previous highest was 146,000 before dipping to 134,000 in our last update. Zepbound's scripts also grew week over week by 9.3%, nearing 667,400 for the week. During the same period, IQVIA tracked slightly shy of 20,000 scripts from Foundayo in its ninth week on the market, compared with nearly 17,000 the prior week. Thanks to the expansion of the oral version, Wegovy overall now commands 42.1% of the obesity market. Tracing backwards, its share has been climbing steadily, clocking in at 41.9%, 41.2%, 41.4%, 40.5%, 40.4%, 42.6% and 40.4% in the past few weeks. Source: IQVIA data cited by Jefferies
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 28 | - | - | ||
| 12 | - | - | ||
| 1 500 | - | - | ||
| 1 710 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
38 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
4,14%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·53 min sittenGemini with a technical analysis of the Novo stock Here is a short and precise technical analysis of Novo Nordisk B (NOVO-B): Trend and Key Figures The stock is currently trading at 287 kr. Short and medium term: The trend is positive. The price has recently broken through resistance at 280 kr. and is above both its 20-day (286 kr.) and 50-day (267 kr.) moving averages. Long term: The trend is negative. The stock is below its 200-day moving average (304 kr.). A Death Cross has also formed (the 50-day average has crossed below the 200-day average), which is a classic sign of weakness for long-term development. Momentum: RSI (Relative Strength Index) is neutral around 52. In the short term, MACD is pointing upwards, while it continues to point downwards in the long run. Support and Resistance Resistance: The first major test is at 304 kr. (the 200-day average) and then around analysts' price target of approx. 311 kr. Support: Downwards, there is strong technical support around 246 kr., and a newer short-term support at the previous resistance level of 280 kr. Dividend and Risk The stock offers a dividend yield of 4.3 % with a healthy payout ratio of approx. 43 %. The stock's technical risk profile is currently classified as high due to an annual standard deviation of over 54 %. Without liability.
- ·10 t sittenUSA closing price 283kr ⬇️⬇️⬇️
- 11 t sitten11 t sittenUPDATE: June 12, 2026 from Jefferies The share of Novo Nordisk's Wegovy pill among total Wegovy scripts appears to have reached a plateau, hovering around one-third over the past few weeks. The latest number for the week ended on June 5 was 33%, compared with 30%, 32% and 31% in the prior weeks, according to Citi. Meanwhile, the obesity market share split between Wegovy and Eli Lilly's Zepbound has been relatively stable at around 40% to 42%, as the Indianapolis pharma's oral Foundayo makes up only a small portion of the market even though its own scripts continue to build. Wegovy's total scripts were up 9.8% on a weekly basis, reaching nearly 484,500. Within this haul, Wegovy pill contributed roughly 159,000, the oral version's highest since its launch. The drug's previous highest was 146,000 before dipping to 134,000 in our last update. Zepbound's scripts also grew week over week by 9.3%, nearing 667,400 for the week. During the same period, IQVIA tracked slightly shy of 20,000 scripts from Foundayo in its ninth week on the market, compared with nearly 17,000 the prior week. Thanks to the expansion of the oral version, Wegovy overall now commands 42.1% of the obesity market. Tracing backwards, its share has been climbing steadily, clocking in at 41.9%, 41.2%, 41.4%, 40.5%, 40.4%, 42.6% and 40.4% in the past few weeks. Source: IQVIA data cited by Jefferies
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 28 | - | - | ||
| 12 | - | - | ||
| 1 500 | - | - | ||
| 1 710 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt